CIBC Private Wealth Group
RARE icon

CIBC Private Wealth Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

CIBC Private Wealth Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$150 – 3514
2025
Q3 		$150 Buy
+5
New +$150 ﹤0.01% 2964
2025
Q2 		– Sell
-43
Closed -$1.34K – 3268
2025
Q1 		$1.34K Buy
+43
New +$1.79K ﹤0.01% 2767
2024
Q2 		– Sell
-19
Closed -$892 – 3273
2024
Q1 		$892 Buy
+19
New +$896 ﹤0.01% 2878
2018
Q3 		– Sell
-118
Closed -$9K – 1543
2018
Q2 		$9K Hold
118
– – ﹤0.01% 1596
2018
Q1 		$6K Hold
118
– – ﹤0.01% 1632
2017
Q4 		$5K Buy
+118
New +$5.79K ﹤0.01% 1691

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIBC Private Wealth Group's RARE Position: Q4 2025 in Review

CIBC Private Wealth Group sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 5 shares — an estimated $150 sold.

CIBC Private Wealth Group first reported a position in RARE in Q4 2017 and held it in 6 quarters. The position peaked at $9K in Q2 2018. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • CIBC Private Wealth Group reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 5 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $150.
  • CIBC Private Wealth Group first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and held it in 6 quarters.
  • CIBC Private Wealth Group's Ultragenyx Pharmaceutical position peaked at $9K in Q2 2018.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.